Ulcerative colitis is a chronic, nonspecific inflammatory bowel disease that primarily affects the rectal and colonic mucosa. Clinical manifestations include recurrent episodes of diarrhea, bloody and mucous stools, and abdominal pain. The disease may be related to the interaction of genetic susceptibility, abnormal immune regulation, gut microbiota imbalance, and environmental factors. Diagnosis requires colonoscopy and pathological biopsy.

Disease characteristics: It mainly affects the mucosa of the colon and rectum, manifesting as recurrent abdominal pain, diarrhea, and bloody mucus stools, and is more common in people aged 20-30.

Etiology and mechanism: It is related to immune disorders, genetic factors, infection and psychological factors, and has a familial aggregation.

Current treatment status: It cannot be completely cured but can be controlled. Mild cases can be relieved in the long term through medication and lifestyle adjustments, while severe cases require medication or surgery to control symptoms.

Whether intestinal ulcers will become cancerous depends heavily on the cause, course of the disease, and treatment, and it is impossible to give a general answer as to how long it will take to develop cancer. Most intestinal ulcers (such as those caused by common infections or medications) do not directly become cancerous, but long-term inflammatory bowel disease (such as ulcerative colitis) may increase the risk of cancer and requires regular follow-up.

Major Risk Factors for Intestinal Ulcer Malignancy

Etiological types1.
Inflammatory bowel disease (IBD) , including ulcerative colitis and Crohn’s disease , is a major high-risk type of intestinal ulcer cancer. The longer the disease duration (especially more than 10 years) and the wider the extent of lesions (such as involvement of the entire colon), the higher the risk of cancer

01. Genetic factors
Some patients exhibit familial clustering, associated with gene mutations such as NOD2 and IL23R. These patients typically experience earlier onset and faster disease progression, and may be accompanied by extraintestinal manifestations such as joint pain and erythema nodosum. Treatment requires the use of immunosuppressants such as azathioprine tablets and mesalazine enteric-coated tablets to control inflammation; in severe cases, infliximab for injection may be used as a biological intervention.

2. Immune abnormalities
Overactivation of the intestinal mucosal immune system leads to abnormal T-cell responses, resulting in the production of excessive pro-inflammatory factors such as tumor necrosis factor. Patients often experience persistent abdominal pain accompanied by tenesmus, and colonoscopy reveals diffuse erosion and shallow ulcers. Treatment commonly involves local administration of mesalazine suppositories; moderate to severe cases require combination therapy with prednisone acetate tablets or cyclosporine soft capsules to modulate the immune system.

03. Dysbiosis
A decrease in the number of beneficial gut bacteria and an overgrowth of pathogenic bacteria can damage the mucosal barrier. Patients experience a significant increase in bowel movements, with undigested food residue visible in the stool. In addition to standard medication, it is recommended to use Bifidobacterium triple live bacteria capsules to regulate the gut microbiota and avoid long-term use of antibiotics which could worsen gut flora imbalance.

04. Environmental factors
High-fat diets, smoking, and mental stress can trigger or worsen the condition. These patients often experience intermittent symptoms, with spasmodic abdominal pain and bloody stools during flare-ups. Treatment requires eliminating the triggering factors. Mild cases can use sulfasalazine enteric-coated tablets, while supplementing with compound glutamine enteric-coated capsules to repair the intestinal mucosa.

05. Risk of complications
If left uncontrolled for a long period, it may progress to toxic megacolon, intestinal perforation, or cancer. Patients experiencing persistent high fever, abdominal distension, or sudden weight loss should be monitored closely. In addition to intensive drug treatment, total colectomy may be necessary, with regular postoperative colonoscopy monitoring for dysplasia.

:-Patients with ulcerative colitis should maintain a low-residue, high-protein diet and avoid dairy products and spicy or irritating foods. Bed rest is necessary during the acute phase, while low-intensity exercise such as walking is permissible during remission. Strictly adhere to the doctor’s prescribed medication regimen and have regular colonoscopies, recording the daily stool characteristics and frequency. Seek immediate medical attention if symptoms worsen, such as increased rectal bleeding, persistent fever, or severe abdominal pain.

Changes in bowel habits : such as alternating diarrhea and constipation , or worsening of rectal bleeding.
Weight loss or anemia : emaciation and weakness without obvious cause.
Symptoms of intestinal obstruction include abdominal pain, abdominal distension, and vomiting.
IV. Summary
Intestinal ulcers do not necessarily become cancerous, but the outcome depends on the specific circumstances:

The probability of ordinary intestinal ulcers becoming cancerous is extremely low, and they can be cured with timely treatment.
Inflammatory bowel disease requires long-term, standardized treatment and regular check-ups to reduce the risk of cancer.
Individual differences are significant, so it is recommended that a doctor assess the risks and develop a follow-up plan based on the specific condition.